Home / Business and Economy / Teva Pharma Raises Guidance Fueled by Key Medicines
Teva Pharma Raises Guidance Fueled by Key Medicines
30 Jul
Summary
- Teva's innovative medicines portfolio showed strong growth in the second quarter.
- AUSTEDO, UZEDY, and AJOVY are driving Teva's revenue and guidance increases.
- Company raised full-year revenue outlook for key products and overall guidance.
Teva Pharmaceutical Industries reported second-quarter 2026 revenue of approximately $4.1 billion, a slight decrease year-over-year in U.S. dollars. This was primarily due to lower sales from generic Revlimid, which were offset by significant growth within its innovative medicines portfolio.
Driving this expansion are AUSTEDO, AJOVY, and UZEDY. AUSTEDO, Teva's treatment for tardive dyskinesia and Huntington's disease, saw U.S. revenue increase by 33% to $676 million last quarter, with global revenue up 40%. The company revised AUSTEDO's 2026 revenue guidance upward, with the midpoint now reaching its previously stated 2027 target.
UZEDY, a long-acting injectable for schizophrenia, experienced a 43% year-over-year revenue increase to $77 million. AJOVY, Teva's migraine treatment, generated $244 million globally, marking a 56% increase. Teva has significantly boosted the full-year outlook for both UZEDY and AJOVY, reflecting their strong market performance.
Looking ahead, Teva anticipates a potential FDA decision in the fourth quarter for its long-acting injectable olanzapine product, with a U.S. launch expected thereafter. The company anticipates no revenue contribution from this product in the fourth quarter of 2026 as coverage is established.
